-
1
-
-
0026606194
-
Analytical method validation: Bioavailability, bioequivalence and pharmaceutical studies
-
Shah VP, Midha KK, Dighe SV et al.Analytical method validation: bioavailability, bioequivalence and pharmaceutical studies. Pharm. Res. 9, 588-592 (1992).
-
(1992)
Pharm. Res.
, vol.9
, pp. 588-592
-
-
Shah, V.P.1
Midha, K.K.2
Dighe, S.V.3
-
2
-
-
0028936323
-
Application issues in bioanalytical method validation, sample analysis and data reporting
-
Dadgar D, Burnett PE, Choc MG et al. Application issues in bioanalytical method validation, sample analysis and data reporting. J. Pharm. Biomed. Anal. 13, 89-97 (1995)
-
(1995)
J. Pharm. Biomed. Anal.
, vol.13
, pp. 89-97
-
-
Dadgar, D.1
Burnett, P.E.2
Choc, M.G.3
-
4
-
-
0034469255
-
Bioanalytical method validation - A visit with a decade of progress
-
Shah VP, Midha KK, Findlay JW et al. Bioanalytical method validation - a visit with a decade of progress. Pharm. Res. 17, 1551-1557 (2000).
-
(2000)
Pharm. Res.
, vol.17
, pp. 1551-1557
-
-
Shah, V.P.1
Midha, K.K.2
Findlay, J.W.3
-
5
-
-
0003484310
-
-
US FDA, US Department of Health and Human Services. US FDA, Center for Drug Evaluation and Research, Rockville, MD, USA
-
US FDA. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services. US FDA, Center for Drug Evaluation and Research, Rockville, MD, USA (2001).
-
(2001)
Guidance for Industry: Bioanalytical Method Validation
-
-
-
6
-
-
79951768879
-
The 2nd Calibration and Validation Group Workshop on recent issues in good laboratory practice bioanalysis
-
Savoie N, Booth BP, Bradley T et al. The 2nd Calibration and Validation Group Workshop on recent issues in good laboratory practice bioanalysis. Bioanalysis 1, 19-30 (2009).
-
(2009)
Bioanalysis
, vol.1
, pp. 19-30
-
-
Savoie, N.1
Booth, B.P.2
Bradley, T.3
-
7
-
-
84906669830
-
-
US FDA. US Department of Health and Human Services. US FDA, Center for Drug Evaluation and Research, Office of Generic Drugs, Rockville, MD, USA
-
US FDA. Correspondence to Aripiprazole ANDA Applicant on September 28, 2006. US Department of Health and Human Services. US FDA, Center for Drug Evaluation and Research, Office of Generic Drugs, Rockville, MD, USA (2006).
-
(2006)
Correspondence to Aripiprazole ANDA Applicant on September 28, 2006
-
-
-
8
-
-
33847184252
-
Workshop/conference report - Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays
-
Viswanathan CT, Bansal S, Booth B et al. Workshop/conference report - quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J. 9, E30-E42 (2007).
-
(2007)
AAPS J.
, vol.9
-
-
Viswanathan, C.T.1
Bansal, S.2
Booth, B.3
-
9
-
-
68249147642
-
Workshop report and follow-up - AAPS workshop on current topics in GLP bioanalysis: Assay reproducibility for incurred samples - Implications of Crystal City recommendations
-
Fast DM, Kelley M, Viswanathan CT et al. Workshop report and follow-up - AAPS workshop on current topics in GLP bioanalysis: assay reproducibility for incurred samples - implications of Crystal City recommendations. AAPS J. 11, 238-241 (2009).
-
(2009)
AAPS J.
, vol.11
, pp. 238-241
-
-
Fast, D.M.1
Kelley, M.2
Viswanathan, C.T.3
|